Skip Navigation
November 18, 2019

Codak Biosciences | Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotides-loaded exosomes results in potent single-agent antitumor activity

Codiak presented data at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy demonstrating the potential of engineered exosomes incorporating an antisense oligonucleotide (ASO) to selectively reprogram tumor-associated macrophages and generate potent anti-tumor activity.